By using appropriate and precise biomarkers, such as NLR and CD8+/Treg ratio, the present comprehensive immunotherapy could be more beneficial for patients with pancreatic carcinoma. The gene discussed is CD8A; the disease is exocrine pancreatic carcinoma.